Crispr Therapeutics Earnings Estimate
| CRSP Stock | USD 65.13 10.04 18.22% |
Crispr Therapeutics Earnings Estimation Breakdown
The calculation of Crispr Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Crispr Therapeutics is estimated to be -1.335875 with the future projection ranging from a low of -1.6775 to a high of -0.8525. Please be aware that this consensus of annual earnings estimates for Crispr Therapeutics AG is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.68 Lowest | Expected EPS | -0.85 Highest |
Crispr Therapeutics Earnings Projection Consensus
Suppose the current estimates of Crispr Therapeutics' value are higher than the current market price of the Crispr Therapeutics stock. In this case, investors may conclude that Crispr Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Crispr Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 28 | 41.04% | 0.0 | -1.335875 | -4.49 |
Crispr Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Crispr Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Crispr Therapeutics AG predict the company's earnings will be in the future. The higher the earnings per share of Crispr Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Crispr Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Crispr Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Crispr Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Crispr Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Crispr Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-30 | 2025-03-31 | -1.2768 | -1.58 | -0.3032 | 23 | ||
2025-02-11 | 2024-12-31 | -1.1856 | -0.44 | 0.7456 | 62 | ||
2024-11-04 | 2024-09-30 | -1.42 | -1.01 | 0.41 | 28 | ||
2024-08-05 | 2024-06-30 | -1.52 | -1.49 | 0.03 | 1 | ||
2024-05-08 | 2024-03-31 | -1.33 | -1.43 | -0.1 | 7 | ||
2024-02-21 | 2023-12-31 | -0.07 | 1.1 | 1.17 | 1671 | ||
2023-11-06 | 2023-09-30 | -1.95 | -1.41 | 0.54 | 27 | ||
2023-08-07 | 2023-06-30 | -2.12 | -0.98 | 1.14 | 53 | ||
2023-05-08 | 2023-03-31 | -1.7 | -0.67 | 1.03 | 60 | ||
2023-02-21 | 2022-12-31 | -2.3 | -1.41 | 0.89 | 38 | ||
2022-11-01 | 2022-09-30 | -2.29 | -2.24 | 0.05 | 2 | ||
2022-08-08 | 2022-06-30 | -2.23 | -2.4 | -0.17 | 7 | ||
2022-05-09 | 2022-03-31 | -1.94 | -2.32 | -0.38 | 19 | ||
2022-02-15 | 2021-12-31 | -1.77 | -1.84 | -0.07 | 3 | ||
2021-11-03 | 2021-09-30 | -1.76 | -1.67 | 0.09 | 5 | ||
2021-07-29 | 2021-06-30 | 3.52 | 9.44 | 5.92 | 168 | ||
2021-04-27 | 2021-03-31 | -1.47 | -1.51 | -0.04 | 2 | ||
2021-02-16 | 2020-12-31 | -1.27 | -1.5 | -0.23 | 18 | ||
2020-10-28 | 2020-09-30 | -1.18 | -1.32 | -0.14 | 11 | ||
2020-07-27 | 2020-06-30 | -0.95 | -1.3 | -0.35 | 36 | ||
2020-04-28 | 2020-03-31 | -1.05 | -1.15 | -0.1 | 9 | ||
2020-02-12 | 2019-12-31 | -0.63 | 0.51 | 1.14 | 180 | ||
2019-10-28 | 2019-09-30 | -0.95 | 2.4 | 3.35 | 352 | ||
2019-07-29 | 2019-06-30 | -0.9 | -1.01 | -0.11 | 12 | ||
2019-04-29 | 2019-03-31 | -0.88 | -0.93 | -0.05 | 5 | ||
2019-02-25 | 2018-12-31 | -0.78 | -0.92 | -0.14 | 17 | ||
2018-11-07 | 2018-09-30 | -0.74 | -1.07 | -0.33 | 44 | ||
2018-08-07 | 2018-06-30 | -0.63 | -0.82 | -0.19 | 30 | ||
2018-05-08 | 2018-03-31 | -0.67 | -0.62 | 0.05 | 7 | ||
2018-03-08 | 2017-12-31 | -0.67 | 0.0034 | 0.6734 | 100 | ||
2017-11-08 | 2017-09-30 | -0.6 | -0.62 | -0.02 | 3 | ||
2017-08-10 | 2017-06-30 | -0.62 | -0.56 | 0.06 | 9 | ||
2017-05-11 | 2017-03-31 | -0.61 | -0.54 | 0.07 | 11 | ||
2017-03-10 | 2016-12-31 | -0.49 | 1.42 | 1.91 | 389 | ||
2016-11-22 | 2016-09-30 | -0.72 | -2.77 | -2.05 | 284 |
About Crispr Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Crispr Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Crispr Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Crispr Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.4 B | -1.3 B | |
| Retained Earnings Total Equity | -761.5 M | -723.4 M | |
| Earnings Yield | (0.11) | (0.12) | |
| Price Earnings Ratio | (9.07) | (9.52) | |
| Price Earnings To Growth Ratio | (0.07) | (0.07) |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Crispr Stock
Moving against Crispr Stock
| 0.44 | BCH | Banco De Chile Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.